PASCALL Systems

PASCALL Systems operates at the intersection of medical devices, brain monitoring, and anesthesia care. Its stated focus is narrower than general patient-monitoring systems: it is developing EEG-based tools intended to help clinicians assess brain activity during general anesthesia. The M0 brain monitor received FDA clearance in 2022, while the company’s described product offering includes a wireless EEG system. Its stated differentiation is an anesthesia index designed to better reflect EEG patterns in older adults, alongside a focus on brain-state information that conventional vital signs may not capture. This positions the company around a specific clinical monitoring problem rather than a broad diagnostic or hospital-device portfolio. Its categories—Medical Device, Manufacturing, and Product Design—also reflect a hardware-oriented development profile. More evidence on adoption, clinical validation, and product availability would be needed to assess its competitive standing.

PASCALL Systems was founded in 2018, and the most concrete inflection point in its available development history is the FDA clearance of its M0 brain monitor in 2022. The company’s product focus remains centered on wireless EEG monitoring during general anesthesia, with an anesthesia index intended to better account for age-related EEG differences. Overall, the information supports a trajectory from founding to a cleared device and continued product development, but not a conclusion about current growth rate. Commercial uptake, subsequent regulatory milestones, financing, and hiring data would be useful indicators of the next stage.